Table of Contents

List of figures..... **i-v**

List of tables..... **vi-vii**

List of schemes..... **viii**

List of abbreviations..... **ix**

List of symbols..... **x**

Preface..... **xi**

Chapters **Page No.**

1. Introduction..... **1-14**
1.1. Alzheimer's disease (AD)..... **1-2**
1.2. Statistics of AD..... **2-3**
1.3. Pathophysiology of AD..... **3-12**
1.3.1. Role of acetyl and butyrylcholines in AD..... **3-5**
1.3.2. Role of amyloid beta (Aβ) and tau proteins in AD..... **5-7**
1.3.3. Role of metals in AD..... **7-9**
1.3.4. Role of oxidative stress in AD..... **9-11**
1.3.5. Role of β-secretase in AD..... **11-12**
1.4. Current drug targets for AD..... **12-14**
1.4.1. Cholinesterases (ChEs) **12-13**
1.4.1.N-methyl-D-aspartate (NMDA) receptor **14**
2. Literature Review..... **15-50**
2.1. Current therapies for AD..... **15-17**
2.1.1. Cholinesterase inhibitors (ChEIs) **15-16**
2.1.2. Noncompetitive NMDA antagonists..... **16-17**
2.2. Antioxidant therapy for AD..... **17-18**
2.3. Ferulic acid (FA) and AD..... **18-21**
2.4. FA as a potential therapeutic agent for AD..... **21-24**
2.4.1. Water-soluble ferulic acid (FA) derivatives..... **21**
2.4.2. Dimeric derivative of FA..... **22**
2.4.3. Development of FA ester as a memory enhancer..... **23-24**
2.5. FA based hybrid molecules for AD..... **25-51**
2.5.1. FA-Donepezil based hybrid molecules for AD..... **24-29**
2.5.1.1. FA-alkylamine-benzylpiperidine hybrids (FAHs)..... **24-25**
2.5.1.2. *N*-benzylpiperidine (NBP)-FA hybrid derivatives..... **25-26**
2.5.1.3. FA-O-alkylamine derivatives..... **26**
2.5.1.4. FA-N-alkyl benzyl piperidinediamide derivative..... **27**
2.5.2. FA-tacrine based hybrid molecules for AD..... **30-34**
2.5.2.1. FA-tacrine alkylenediamine hybrid molecules (TFAHs)..... **30**
2.5.2.2. FA-tacrine-diamide side-chain derivatives..... **30**
2.5.2.3. FA-ethylenediamine tacrine derivatives..... **31**
2.5.2.4. FA-tacrine-melatonin hybrids (FATMHs)..... **32**
2.5.2.5. FA-tacrine piperazine amine side chain hybrids..... **33**
2.5.2.6. FA tacrine-nitric oxide donor trihybrid derivatives..... **33-34**
2.5.3. FA-rivastigmine derivatives..... **37**
2.5.4. FA-N-benzyl-piperidine and N, N-dibenzyl (N-methyl) amine derivatives. **37-38**
2.5.5. FA and memantine derivatives..... **38-39**
2.5.6. FA-isoquinoline hybrids..... **39-40**

2.5.7. FA-*O*-carbamoyl ferulamide derivative…… **40-41**
2.5.8. FA–carbazole hybrid derivatives……**41-42**
2.5.9. FA-tertiary amine side chain derivatives……**42-43**
2.5.10. FA-mamoquin hybrids…… **43**
2.5.11. Isosorbide-2-benzylcarbamate-5-ferulate or lipoic acid ester derivatives…**47**
2.5.12. FA and 1,3,4-oxadiazole derived hybrids…… **48**
2.5.13. 7-*O*-Esters of taxifolin and FA derived hybrids…….. **48-49**
2.5.14. FA-quinolone hybrids…….. **49**
2.5.15. FA-berberine hybrid analogs……**49-50**
3. Objectives, Rational and Plan of Work…… **51-57**
3.1. Objectives and Rationale…….. **53-54**
3.2. Plan of Work…… **56**
3.2. Schemes for the synthesis of FA template based novel compounds ……**57-58**
4. Results and Discussion……**58-138**
4.1. Chemistry involved in synthesizing the first series of compounds……**58-59**
4.2. Biological evaluation of the first series of compounds……**59**
4.2.1. *In-vitro* cholinesterases inhibition (AChE and BChE) studies……... **59-68**
4.2.2. Evaluation of antioxidant property…… **69-70**
4.2.3. *In-vitro* cholinesterases (AChE and BChE) inhibition kinetic studies with the lead molecules……...**71**
4.2.4. Measurement of propidium iodide displacement from the peripheral anionic site (PAS) of AChE…… **72**
4.2.5. Evaluation of iron chelation property of the lead molecules…….. **72-74**
4.2.6. Evaluation of $A\beta_{1-42}$ aggregation modulation activity of lead molecule **75-76**
4.2.7. Molecular docking study with AChE and BChE……**77-78**
4.2.8. Molecular dynamics (MD) simulation studies with AChE…… **78-79**
4.2.9. Molecular dynamics (MD) simulation studies with BChE……**80-81**
4.2.10. Calculation of physicochemical parameters……... **81-83**
4.2.11. Evaluation of cytotoxicity of lead molecule……**83-84**
4.2.12. Neuroprotection studies with **7a (F24)** on H_2O_2 induced cell death and morphological alterations…… **84-87**
4.2.13. Intracellular ROS modulation studies with **7a** (**F24**)……**87-88**
4.2.14. Protective effects of **7a (F24)** against H_2O_2-induced DNA fragmentation and apoptosis……**88-89**
4.2.15. Neuroprotection Studies against $A\beta_{1-42}$ induced aggregation modulation property of **7a** (**F24**)…… **90**
4.2.16. *In-vitro* blood-brain barrier (BBB) permeation study…….. **91**
4.2.17. Evaluation of *in-vivo* efficacy of **7a** in the AD model of Drosophila.. **92-93**
4.2.18. Molecular docking and dynamics simulations studies of **7a (F24)** with $A\beta_{1-42}$ fibrils …… **94-96**
4.2.19. Evaluation of $A\beta_{1-42}$ fibrils disintegration property of **7a (F24)** using molecular dynamics simulations…… **96-99**
4.2.20. Principal component analysis (PCA) of protofibril and protofibril-**7a (F24)** complex…… **99-100**
4.2.21. Acute toxicity studies on mice…… **101**
4.2.22. Evaluation of *in-vivo* efficacy of **7a** in scopolamine-induced AD mice model
4.2.23. Ex-vivo neurochemicals estimation and antioxidant property evaluation..**103**
4.2.24. Evaluation of *in-vivo* efficacy of **7a** (**F24**) in scopolamine-induced AD mice model (Watermaze)…….. **105-107**
4.3.1. Chemistry involved in synthesizing the second series of compounds…….. **108**
4.3.2. Biology involved with the second series of compounds…… **108**
4.3.2.1. Design of second series of novel naturally inspired FA analogs…… **108-110**
4.3.2.2. Cholinesterases inhibition studies…….. **110-116**
4.3.2.3. Antioxidant activity (DPPH radical scavenging activity)…….. **117-118**

4.3.2.4. Kinetic studies of ChEs inhibition…….. **118-119**
4.3.2.5. Peripheral anionic site (PAS) binding study…….. **119-120**
4.3.2.6. Molecular modeling studies…….. **120-131**
4.3.2.6.1. Molecular docking…… **120-122**
4.3.2.6.2. Interaction of ligands **13k** and **23b** with hAChE…… **122-125**
4.3.2.6.3. Interaction of ligands **13k** and **23b** to hBChE…… **125-127**
4.3.2.6.4. Analysis of binding free energy…….. **127-129**
4.3.2.6.5. Analysis of structural stability, compactness and solvent accessbility surface area…….. **129-131**
4.3.2.7. Calculation of physicochemical parameters…… **129-130**
4.3.2.8. Metal chelation study…….. **132-133**
4.3.2.9. *In-vitro* evaluation of cytotoxicity of compound **23b**……..……**134**
4.3.2.10. Neuroprotective effect of **23b** on H_2O_2 induced SH-SY5Y cell injury….**135**
4.3.2.11. *In-vitro* blood-brain barrier permeation assay……..**136**
4.3.2.12. **23b** ameliorates scopolamine-induced cognitive impairment in the Morris water maze test…… **137-139**
5. Experimental Section…… **140-192**
5.1. Materials and methods……. **140-169**
5.2. Biological evaluation…… **169-192**
6. Summary and Conclusions…… **193-198**
References…… **199-215**
Appendix……..…….**216-227**
List of Publications…… **228-229**
Curriculum Vitae…… **230-234**

List of Figures

Figure No.	Description	Page No.
1.1	Diagrammatic representation of acetylcholine synthesis, metabolism, and its mode of action.	**4**
1.2	Mechanism of substrate cleavage through AChE.	**5**
1.3	Fenton reaction by which H_2O_2 forms hydroxyl radical in iron rich environment.	**8**
1.4	Schematic representation of role of iron in AD.	**9**
1.5	Diagrammatic representation indicating the role of ROS and metals in AD progression.	**10**
1.6	Diagrammatic representation indicating the role of β-secretase in Aβ aggregation.	**11**
1.7	Schematic view of the active site of AChE.	**13**
1.8	NMDA receptor complex as therapeutic target in AD.	**14**
2.1	Chemical structures of the drugs for the treatment of AD.	**17**
2.2	Chemical structures of the natural products known for the anti-AD effect.	**18**
2.3	Structures of novel ferulate ester derivatives with improved water solubility and potency in AD model.	**22**
2.4	Chemical structures of ferulic acid (**FA**)-donepezil (DPZ) based hybrid molecules.	**28**
2.5	Chemical structures of **FA**-tacrine derived hybrid molecules.	**34**
2.6	Chemical structures of **FA**-rivastigmine based hybrid molecules hybrid.	**37**
2.7	Chemical structures of various developed potent hybrids based on ferulamide derivatives of NBP, DMBA, tetrahydroisoquinoline and memantine.	**40**
2.8	Chemical structures of potent **FA** based hybrid analogs derived using fragments from memoquin, rivastigmine, carbazole, and tertiary amine side chain.	**44**
2.9	Chemical structures of **FA** based miscellaneous hybrid analogs.	**50**
3.1	Overview of the designed study.	**54**
4.1	2D interaction diagram of (A) DPZ and (B) FA with various amino acids of the AChE cavity.	**61**
4.2	Overlay of docked donepezil and co-crystallized donepezil.	**61**

4.3	Schematic pipeline toward the development of novel **FA** derivatives with favorable properties.	**62**
4.4	2D interaction diagram of (A) **4f** with AChE (PDB #4EY7); (B) **4f** with BChE (PDB #4BDS); (C) **7a** with AChE; and (D) **7a** with BChE.	**65**
4.5	Binding interactions (2D) of **7a** (A) Pose I and (B) Pose II with various amino acids of AChE active cavity (two different binding modes).	**66**
4.6	Binding interactions (2D) of **10b** with various amino acids of AChE active cavity.	**68**
4.7	Structural optimization and a brief summary of SAR with **FA** analogs.	**68**
4.8	Percent radical scavenging activity of **4f**, **4g**, **4i**, **4j**, **7a**, **7b**, **10b** and **FA**.	**69**
4.9	Proposed mechanism for radical scavenging activity of **7a**.	**70**
4.10	Kinetics study on the mechanism of ChE inhibition by compound **7a**.	**71**
4.11	UV absorbance spectrum of compounds **7a** and **4f** alone and in the presence of $FeCl_3$ in water at various pH.	**74**
4.12	Inhibition of self-induced $A\beta_{1-42}$ aggregation in the presence of **7a**, **FA** and DPZ. (AFM images).	**76**
4.13	(A) Docked pose of **7a** and acetylcholine into the active site of AChE. (B) Overlaid docked pose of **7a** and DPZ into the active site of AChE.	**78**
4.14	(A) Protein-ligand RMSD. (B) RMSF (C) **7a** interactions with the key amino acid residues. (D) Bar charts of protein interaction with ligand **7a** as monitored throughout the simulation.	**79**
4.15	(A) Protein RMSD and ligand RMSD indicate the stability of the ligand **7a** with respect to BChE and its active pocket. (B) RMSF plot based on Cα atoms of BChE for the BChE–**7a** complex.	**80**
4.16	The simulation interactions diagram (SID) plot showing the protein-ligand interactions between the amino acid residues of the BChE binding site and **7a**.	**81**
4.17	Binding interactions (2D) of **7a** with various amino acids of BChE (PDB ID: 4BDS) active site.	**81**
4.18	Effect of **7a** on cell viability.	**84**
4.19	Effect of **7a** (**F24**) against H_2O_2 mediated cell death.	**85**

4.20	Representative images of SH-SY5Y cells morphological alterations induced by H_2O_2 and the effect of **7a** (**F24**).	**87**
4.21	Intracellular ROS modulation studies with **7a** (**F24**).	**88**
4.22	Detection of TUNEL-positive apoptotic strand breaks.	**89**
4.23	Protective effect of **7a** (**F24**) against Aβ induced cell death.	**91**
4.24	The histogram represents the *in-vivo* effects of **7a** (**F24**) on wild type and $A\beta_{42}$ expressing flies.	**93**
4.25	(A) Interaction of **7a** (**F24**) with $A\beta_{1-42}$ protofibrils. (B) Surface representation **7a** (**F24**) docked into the pocket of $A\beta_{1-42}$ protofibrils. (C) 2D interaction diagram of **7a** (**F24**) with $A\beta_{1-42}$ protofibril.	**94**
4.26	Binding free-energy (kJ/mol) contribution of critical individual residues of different chains in binding **7a** (**F24**) to $A\beta_{1-42}$ protofibril.	**95**
4.27	(A) RMSD, (B) radius of gyration, (C) solvent accessibility surface area, and (D) change in secondary structure content of protofibrils and protofibrils-**7a** (**F24**) complex obtained from molecular dynamics simulation data.	**97**
4.28	Root mean square fluctuation (RMSF) of each residue for $A\beta_{42}$ and $A\beta_{1-42}$-**F24** complex	**98**
4.29	Projection of the motion of (A) $A\beta_{1-42}$, and (B) $A\beta_{1-42}$-F24 complex in phase space along the first two principal eigenvectors at 300 K.	**100**
4.30	The eigenvalue rank along with proportion of variance (%) for (A) $A\beta_{1-42}$ and (B) $A\beta_{1-42}$-**F24** complex.	**100**
4.31	Histomorphological appearance of liver of mice.	**101**
4.32	Scopolamine-induced memory deficit in mice.	**103**
4.33	The *ex-vivo* AChE, BChE and antioxidant effect of DPZ, compound **7a** (**F24**), **FA** and scopolamine.	**104**
4.34	Scopolamine-induced memory deficit mice model study.	**106**
4.35	Design of the multifunctional ChEs inhibitors by integrating the structural features of **FA** derivatives.	**113**
4.36	ChEs inhibitory activities of selected compounds.	**114**
4.37	Brief summary of structural activity relationship (SAR).	**115**
4.38	DPPH scavenging activity by **13k**, **23a**, **23b**, **23c** and **FA**.	**117**

4.39	Lineweaver-Burk double reciprocal plot showing the mechanism of *h*AChE and *eq*BChE inhibition over a range of substrate concentrations	**118**
4.40	2D interaction diagram of (A) **13k** with AChE, (B) **23b** with AChE, (C) **13k** with BChE, and (D) **23b** with BChE.	**122**
4.41	Interactions fraction histogram of (A) DPZ, (B) **13k**, and (C) **23b** with hAChE.	**123**
4.42	Top panel shows the total number of specific contacts the *h*AChE makes with the (A) DPZ, (B) **13k**, and (C) **23b** over the course of the trajectory frame.	**124**
4.43	Interactions fraction histogram of (A) Tacrine, (B) DPZ, (C) **13k**, and (D) **23b** with *h*BChE.	**125**
4.44	Top panel shows the total number of specific contacts the *h*BChE makes with the (A) Tacrine, (B) DPZ, (C) **13k**, and (D) **23b** over the course of the trajectory frame.	**126**
4.45	Binding free energy of (A) AChE with ligands **13k** and **23b**, and (B) BChE with ligands **13k**, and **23b**	**127**
4.46	Backbone RMSD plot for (A) apo-AChE in comparison with AChE-DPZ, AChE-**13k**, and AChE-**23b**, (B) apo-BChE in comparison with BChE-DPZ, BChE-Tacrine, BChE-**13k**, and BChE-**23b**.	**128**
4.47	The radius of gyration plot for (A) apo-AChE in comparison with AChE-DPZ, AChE-**13k**, and AChE-**23b**, and (B) apo-BChE in comparison with BChE-DPZ, BChE-Tacrine, BChE-**13k**, and BChE-**23b**.	**129**
4.48	Percentage decrease in SASA of active site residues (20 Å) away from the bound ligand) of (A) AChE and (B) BChE.	**129**
4.49	2D interaction diagram of (A) *h*AChE with DPZ (B) *h*BChE with DPZ and (C) *h*BChE with Tacrine.	**130**
4.50	UV absorbance spectra of **23b** alone or in the presence of $FeCl_3$ in methanol (pH 4.2 and 7.4).	**132**
4.51	Effect of **23b** on cell viability.	**133**
4.52	Effect of **23b** against H_2O_2 mediated cell death.	**134**
4.53	Schematic schedule of experimental design to study the anti-amnestic effect of compound **23b**.	**137**

4.54	Escape latency time (in second) from Day 1 to Day 4.	**137**
4.55	Scopolamine-induced memory deficit mice model study.	**138**
A1-A3	^{1}H-NMR, ^{13}C-NMR and HRMS spectra of (*E*)-N-(4-hydroxy-3-methoxyphenyl)-N-(2-((3-methoxyphenyl)amino)-2oxoethyl)acrylamide (**4f**).	**216-218**
A4-A6	^{1}H-NMR, ^{13}C-NMR and HRMS spectra of (*E*)-N-(2-((1H-indol-5-yl) amino)-2-oxoethyl)-3-(4-hydroxy-3-methoxyphenyl)acrylamide (**7a**).	**219-221**
A7-A9	^{1}H-NMR, ^{13}C-NMR and HRMS spectra of (*E*)-1-(4-(3-fluorobenzyl) piperazin-1-yl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one (**13k.HCl**).	**222-224**
A10-A12	^{1}H-NMR, ^{13}C-NMR and HRMS spectra of (*E*)-3-(4-hydroxy-3-methoxyphenyl)-N-(2-((2-(5-methoxy-1H-indol-3-yl)ethyl)amino)-2-oxoethyl)acrylamide (**23b**).	**225-227**

List of Tables

Table No.	Description	Page No.
2.1	*In-vitro* biological data for evaluating the therapeutic potential of hybrid analogs based on novel ferulic acid (**FA**)-donepezil (DPZ) and their mode of action.	**29**
2.2	In-vitro biological data for the evaluation of the therapeutic potential of hybrid analogs based on novel **FA**-tacrine-based hybrid analogs and their mode of action.	**35-36**
2.3	*In-vitro* biological data for evaluating the therapeutic potential of hybrid analogs based on **FA** and their mode of action.	**45-46**
4.1	Cholinesterase inhibitory activities of the target compounds.	**67-68**
4.2	Antioxidant activity (DPPH assay) of **4f**, **4g**, **4i**, **4j**, **7a, 10b,** and **FA**.	**70**
4.3	Displacement of propidium iodide from the peripheral anionic site of AChE by **7a**, **FA** and DPZ at the indicated concentrations.	**72**
4.4	Theoretical prediction of physiochemical parameters of the developed compounds.	**82-83**
4.5	Permeability in the PAMPA-BBB assay for **7a**, testosterone, imipramine, corticosterone, hydrocortisone, and DPZ with their predictive BBB-penetration.	**91**
4.6	Binding free energy between $A\beta_{1-42}$ protofibrils and **7a (F24)** in the last 10 ns MD simulation.	**96**
4.7	Time-average and standard deviation of RMSD, Rg, and SASA value along with the sum of Eigen values for $A\beta_{1-42}$ protofibril and $A\beta_{1-42}$ protofibril-**7a** (**F24**) Complex.	**97**
4.8	Average binding free energy along with its individual contributing terms for chain C and D of protofibril in presence and absence of **7a (F24)**.	**99**
4.9	Structures, ChEs inhibitory activities, cLogP, and tPSA of compounds **13a-13p**, **18a-18c** and **23a-23c**.	**113-114**
4.10	Antioxidant activity (DPPH assay) of **13a**, **13c**, **13f**, **13h**, **13i**, **13k-13l**, **18a-18c**, **23a-23c** and **FA**.	**116**

4.11	Displacement of propidium iodide from the peripheral anionic site of AChE by **13k**, **23b**, **23c,** and **DPZ** at the indicated concentrations.	**119**
4.12	Docking results (docking score, XP GScore, glide gscore, and glide emodel) and interaction details between the *h*AChE and different FA analogs.	**120**
4.13	Docking results (docking score, XP GScore, glide gscore, and glide emodel) and interaction details between the BChE and different **FA** analogs.	**120-121**
4.14	The average ΔG_{bind} and its different contributing energy terms for **13k** and **23b** against hAChE and hBChE calculated from MD trajectories (last 25) ns.	**127**
4.15	Calculation of physicochemical parameters of the developed molecules.	**130-131**
4.16	Permeability in the PAMPA-BBB assay for **13k**, **23b**, DPZ, testosterone, corticosterone, and hydrocortisone with their predictive BBB penetration.	**135**

List of Schemes

Schemes	Description	Page No.
Scheme 1	Synthesis of FA-acetamide derivatives **4a-4q**.	**55**
Scheme 2	Synthesis of FA-Indole or quinoline derivatives.	**55**
Scheme 3	Synthesis of FA tethered to *N*-phenyl-piperazine scaffolds **10a-10g**.	**56**
Scheme 4	Synthesis of benzylpiperazine derivatives **13a-13p**.	**56**
Scheme 5	Synthesis of FA-alanine-amide compounds **18a-18c**.	**57**
Scheme 6	Synthesis of FA-tryptamine-glycine amide **23a-23c**.	**57**